What Has Been the Progress and Growth of the Oncology Based In-Vivo CRO Market in Recent Years?
The oncology based in-vivo cro market has seen considerable growth due to a variety of factors.
•In recent times, the oncology-based in-vivo cro market has seen a robust expansion. It is set to rise from $1.39 billion in 2024 to $1.5 billion in 2025, with a compound annual growth rate (CAGR) of 8.0%.
The substantial growth observed in the historical period can be ascribed to factors such as a heightened focus on oncology treatments, rising incidences of cancer, a shift towards tailored medicine, the growth of the pharmaceutical industry, and the demand for target-specific therapies.
What Can Be Expected from the Oncology Based In-Vivo CRO Market in the Coming Years?
The oncology based in-vivo cro market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for in-vivo CRO in oncology is predicted to experience a quick surge in the following years, ballooning to "$2.28 billion by 2029 with a compound annual growth rate (CAGR) of 10.9%.
This growth during the forecast period can be ascribed to the rise of new market opportunities, a transition towards immuno-oncology therapies, an increase in clinical trials for oncology, precision medicine, and targeted therapies. Significant trends occurring during this period include advancements in regenerative medicine and cell therapies, an increased demand for speedy drug development, the rise of digitalization and data analytics, attention on the tumor microenvironment, and an increase in biologics and immunotherapies.
What Main Forces Are Fueling Expansion In The Oncology Based In-Vivo CRO Market?
The escalation in cancer cases is predicted to boost the expansion of the oncology-focused in-vivo Contract Research Organization (CRO) market in the upshots. Cancer basically denotes a cluster of illnesses characterized by abnormal cells multiplying beyond control, crossing their natural limits, emerging in practically any organ or tissue in the body, and circulating via the blood and lymphatic system to other regions of the body. The treatment and diagnosis of this condition necessitate novel medicines and equipment that undergo separate preclinical exams, clinical assessments, and regulatory procedures before they are released to the market. Oncology in-vivo CROs are firms contracted by sponsor companies to offer research services such as carrying out all or a fraction of the steps of conducting a preclinical in-vivo study (which involves testing and witnessing impacts on living organisms like animals, plants or whole cells) before the drug or device is tested on humans. The rising cancer rates have also augmented the demand for innovative treatments and protocols, stimulating the expansion of the oncology-oriented in-vivo CRO market. For instance, in April 2024, the American Cancer Society, a US-based charitable organization, reported roughly 609,000 deaths due to cancer and 1.9 million fresh cancer cases discovered in the nation in 2022. It is also expected that around 620,000 deaths caused by cancer could occur, denoting a minor escalation in deaths in 2024. This escalating dominance of cancer is the key driver of the oncology-rooted in-vitro CRO market.
What Are The Primary Segments In The Global Oncology Based In-Vivo CRO Market?
The oncology based in-vivo cro market covered in this report is segmented –
1) By Indication: Blood Cancer, Solid Tumors, Other Indications
2) By Model: Syngeneic Model, Xenograft, Patient Derived Xenograft (PDX), Other Models
3) By Application: Hospitals, Rehabilitation Centers
Subsegments:
1) By Blood Cancer: Leukemia, Lymphoma, Myeloma
2) By Solid Tumors: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Other Solid Tumors
3) By Other Indications: Neuroblastoma, Germ Cell Tumors, Sarcomas, Other Specific Indications
Pre-Book The Oncology Based In-Vivo CRO Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Key Trends Are Driving Changes In The Oncology Based In-Vivo CRO Market?
Leading firms in the in vivo CRO market targeting oncology are shifting their focus towards personalized oncology models to secure an edge in the market. These personalized models apply patient-derived xenografts (PDXs) to devise customized treatment plans, thereby improving the accuracy and effectiveness of preclinical trials. Charles River Laboratories, an American life sciences company, for example, introduced its OncoMouse platform in 2022. This platform employs PDX technology for enhanced tumor representation. It offers high-throughput screening features and the ability to track tumor growth in real-time, facilitating the speedy evaluation of treatment effects. The platform also incorporates comprehensive data analytics to fine-tune treatment regimes according to each patient's unique profile. These developments point towards a transition to more efficient, patient-focused methods in cancer treatment research.
Who Are the Key Players in the Oncology Based In-Vivo CRO Market?
Major companies operating in the oncology based in-vivo cro market include:
• Crown Bioscience
• Charles River Laboratories International Inc.
• Taconic Biosciences Inc.
• The Jackson Laboratory
• ICON plc.
• WuXi AppTec Inc.
• Eurofins Scientific SE
• Labcorp Drug Development
• Champion Oncology Inc.
• Xentech SAS
• Thermo Fisher Scientific Inc.
• MI Bioresearch Inc.
• Clintec International Private Limited
• Worldwide Clinical Trials Inc.
• Pharm-Olam LLC
• Clinipace Clinical Research Private Limited
• Covance Inc.
• Evotec SE
• Living Tumor Laboratory
• Oncodesign SA
• Pharmaron Beijing Co. Ltd.
• Syngene International Limited
• GenScript Biotech Corporation
• Shanghai Medicilon Inc.
• Oncolys BioPharma Inc.
• Pharmalegacy Laboratories
• Oncotest GmbH
• Oncovision
• Biocytogen LLC
• Innovent Biologics Inc.
What Is The Most Dominant Region In The Oncology Based In-Vivo CRO Market?
North America was the largest region in the oncology-based in-vivo CRO market in 2024.North America is expected to be the fastest-growing region in the global oncology-based in-vivo CRO market report during the forecast period. The regions covered in the oncology-based in-vivo CRO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
